In this study, an in silico screening of 140 FDA approved drugs for neurological treatment was done against the primary targets of AD therapeutics, namely, acetylcholinesterase, BACE-1, and Aβ aggregation. The gene discussed is ACHE; the disease is Alzheimer disease.